LFG
KALV

Larson Financial Group’s KalVista Pharmaceuticals KALV Stock Holding History

Larson Financial Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.4K Buy
1,657
+934
+129% +$15.1K ﹤0.01% 1572
2025
Q4 		$11.7K Buy
723
+33
+5% +$437 ﹤0.01% 2026
2025
Q3 		$8.4K Buy
690
+524
+316% +$7.24K ﹤0.01% 2105
2025
Q2 		$1.88K Buy
166
+22
+15% +$269 ﹤0.01% 2427
2025
Q1 		$1.66K Buy
+144
New +$1.47K ﹤0.01% 2226

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Larson Financial Group's KALV Position: Q1 2026 in Review

Larson Financial Group increased its KalVista Pharmaceuticals (KALV) stake by 129% in Q1 2026, buying an estimated $15.1K and bringing the position to 1,657 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

Larson Financial Group first reported a position in KALV in Q1 2025 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Larson Financial Group held 1,657 shares of KalVista Pharmaceuticals worth $33.4K as of Q1 2026.
  • Larson Financial Group bought 934 KalVista Pharmaceuticals shares in Q1 2026, an estimated $15.1K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1572 holding.
  • Larson Financial Group first reported a position in KalVista Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.